✨ Free AI Report
Nexstim Plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Nexstim Plc
Company Research

Nexstim Plc: Business Overview, Financials & Competitive Analysis

Nexstim Plc scores 5/10 on the AskCyborg Cyborg Score (Mixed). Emerging medtech player with novel brain stimulation technology positioned to address large neurology market, but execution risk remains on clinical trials and commercialization. Nexstim operates in high-potential neurotechnology market with differentiated technology and growing revenue (+19% YoY in 2024). However, the company remains early-stage with modest scale ($10.2M revenue, $70-110M.

What is Nexstim Plc's industry? Nexstim Plc (nexstim.com) operates in Medical Device / Neurotechnology / Brain Stimulation. AskCyborg classifies Nexstim Plc under Medical Device / Neurotechnology / Brain Stimulation in its company registry.

Nexstim is a Finnish medical technology company specializing in navigated transcranial magnetic stimulation (nTMS), a non-invasive brain stimulation technology using electromagnetic pulses to target specific brain reg...

5/ 10Mixed

Cyborg Score thesis

Emerging medtech player with novel brain stimulation technology positioned to address large neurology market, but execution risk...

Read the full analyst-debate transcript →
Industry Medical Device / Neurotechnology / Brain Stimulation
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Nexstim Plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Nexstim Plc

AskCyborg analysts argue the bull and bear cases for Nexstim Plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Nexstim Plc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Nexstim Plc Overview

Pro stress-test →

Nexstim is a Finnish medical technology company specializing in navigated transcranial magnetic stimulation (nTMS), a non-invasive brain stimulation technology using electromagnetic pulses to target specific brain regions. The company develops two primary product platforms: the NBS System for pre-surgical brain mapping and the NBT System for treating major depressive disorder and chronic neuropathic pain.

Strategic Profile

Pro stress-test →

Nexstim differentiates through 3D navigation technology enabling personalized, targeted brain stimulation. The company has established market presence with systems in over 100 clinical facilities globally, with North America representing the majority of revenue. Strategic partnerships, including collaboration with Brainlab and Sinaptica Therapeutics, strengthen product development and commercialization capabilities.

Competitive Landscape

Pro stress-test →

Nexstim competes with established TMS providers including NeuroStar (Magventure), Magstim, and MagVenture. Competitive advantages include advanced navigation technology, presurgical mapping capabilities, and expanding therapeutic pipeline. Primary differentiation is proprietary 3D navigation for personalized targeting, though larger competitors have greater scale and clinical evidence.

Industry Context

Nexstim Plc operates in Medical Device / Neurotechnology / Brain Stimulation.

Key facts

Founded: 2000 · Headquarters: Helsinki, Finland · Employees: 40 · Revenue: $10.2M · Market cap: $70.3M-$110.4M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Nexstim Plc.

  • Revenue grew 19% YoY to $10.2M in 2024 with improving margins; approaching profitability with narrowing net losses
  • NBT System is in Phase III pivotal clinical trial for stroke rehabilitation in U.S., representing critical value inflection point if successful
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2024Corporate partnership deal with Brainlab for integration and collaboration
  • 2024Revenue increased 19% YoY to €10.2M from €8.58M, demonstrating traction and market acceptance
  • +1 moreTrack every material event for Nexstim Plc as it happens. Explore monitoring →
Get alerted when Nexstim Plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

NeuroStarFDA-approved TMS system for depression treatment→Magstim TMSClinical and research TMS equipment provider→MagVenture SystemsTMS and brain stimulation devices for therapy→

Compare Nexstim Plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Nexstim Plc operates in Medical Device / Neurotechnology / Brain Stimulation. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Device / Neurotechnology / Brain Stimulation research →
NEW · MCP server

Ask your AI assistant about Nexstim Plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Nexstim Plc and its top competitor on Cyborg Score”
“What did Nexstim Plc do this quarter?”
“Is Nexstim Plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Nexstim Plc do?+
Nexstim is a Finnish medical technology company specializing in navigated transcranial magnetic stimulation (nTMS), a non-invasive brain stimulation technology using electromagnetic pulses to target specific brain reg...
What is Nexstim Plc's Cyborg Score?+
Nexstim Plc has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Nexstim Plc's main competitors?+
Named competitors include NeuroStar, Magstim TMS, MagVenture Systems. The full competitive landscape is in the AskCyborg report.
How can I get the full Nexstim Plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Nexstim Plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Nexstim Plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Medical Device research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Butterfly Network, Inc.6Beyond Air, Inc.5Nexstim Plc3HeartSciences Inc.